Zoledronic Acid

Generic Name: Zoledronic Acid

Brand Names: Reclast, Zometa

Zoledronic acid is a potent IV bisphosphonate given yearly for osteoporosis or for cancer-related bone conditions.

EndocrineBone HealthOncology

Drug Class

Bisphosphonate (Nitrogen-Containing)

Pregnancy

Category D; contraindicated in pregnancy. Animal studies demonstrated teratogenic effects including skeletal malformations and maternal toxicity. Women of childbearing potential should be advised against becoming pregnant during treatment.

Available Forms

5 mg/100 mL intravenous solution (Reclast) for osteoporosis, 4 mg/5 mL intravenous concentrate (Zometa) for oncology indications

What It's Used For

Dosage Quick Reference

These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.

Condition	Starting Dose	Maintenance Dose
Postmenopausal Osteoporosis (treatment)	5 mg IV infusion over at least 15 minutes once yearly	5 mg IV once yearly; reassess after 3-5 years
Osteoporosis Prevention	5 mg IV infusion once every 2 years	5 mg IV every 2 years
Paget Disease of Bone	5 mg IV single infusion	Additional infusion may be considered after 12 months if relapse occurs
Glucocorticoid-Induced Osteoporosis	5 mg IV infusion once yearly	5 mg IV once yearly for the duration of glucocorticoid therapy

Side Effects

Common Side Effects:

Acute phase reaction (fever, myalgia, arthralgia, headache)
Nausea
Fatigue
Bone pain
Constipation

Serious Side Effects:

Osteonecrosis of the jaw
Atypical femur fractures
Acute renal failure
Severe hypocalcemia
Ocular inflammation (uveitis, scleritis)

Drug Interactions

Aminoglycoside antibiotics (gentamicin, tobramycin): Both zoledronic acid and aminoglycosides can lower serum calcium. Concurrent use increases the risk of prolonged hypocalcemia. Monitor calcium levels closely.
Loop diuretics (furosemide, bumetanide): These increase renal calcium excretion and may potentiate the hypocalcemic effect of zoledronic acid. Ensure adequate hydration.
Nephrotoxic drugs (NSAIDs, certain antivirals, contrast dye): Zoledronic acid is cleared renally and can impair kidney function, especially with dehydration. Avoid concurrent nephrotoxic agents when possible and ensure adequate hydration before infusion.
Other bisphosphonates (alendronate, risedronate): Do not use zoledronic acid (Reclast) concurrently with another bisphosphonate. There is no additive benefit and an increased risk of adverse effects.
Calcium and vitamin D supplements: Not a harmful interaction — in fact, patients should take calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) to prevent hypocalcemia, but these supplements should be taken routinely, not just on the day of infusion.

Additional Information

Zoledronic acid is a potent nitrogen-containing bisphosphonate used for various bone-related conditions including osteoporosis, Paget's disease, hypercalcemia of malignancy, and bone metastases. It is administered intravenously and provides long-lasting effects.

Mechanism of Action

Zoledronic acid inhibits osteoclast-mediated bone resorption:

Binds to hydroxyapatite: Concentrates at sites of active bone turnover
Inhibits farnesyl pyrophosphate synthase: Key enzyme in mevalonate pathway
Disrupts osteoclast function: Prevents prenylation of small GTPases essential for osteoclast activity
Induces osteoclast apoptosis: Results in reduced bone resorption
Most potent bisphosphonate: Higher binding affinity and longer duration than other bisphosphonates

Available Formulations

Reclast: 5 mg/100 mL (for osteoporosis, Paget's disease)
Zometa: 4 mg/5 mL concentrate, 4 mg/100 mL premixed (for oncology indications)

Different formulations are NOT interchangeable.

Medical Uses

FDA-Approved Indications:

Reclast (5 mg annually):

Treatment and prevention of postmenopausal osteoporosis
Treatment of osteoporosis in men
Treatment and prevention of glucocorticoid-induced osteoporosis
Paget's disease of bone

Zometa (4 mg):

Hypercalcemia of malignancy
Bone metastases from solid tumors (with standard antineoplastic therapy)
Multiple myeloma bone disease

Dosing Guidelines

Osteoporosis (Reclast):

5 mg IV once yearly (treatment)
5 mg IV every 2 years (prevention)
Infuse over at least 15 minutes

Paget's Disease (Reclast):

5 mg IV as a single dose
Retreatment may be considered after 12 months

Hypercalcemia of Malignancy (Zometa):

4 mg IV over at least 15 minutes
Consider retreatment after 7 days if needed

Bone Metastases/Multiple Myeloma (Zometa):

4 mg IV every 3-4 weeks
Infuse over at least 15 minutes

Important Safety Information

Contraindications:

Hypocalcemia (correct before administration)
CrCl <35 mL/min (osteoporosis) or as specified for oncology
Known hypersensitivity to zoledronic acid or bisphosphonates

Warnings and Precautions:

Acute phase reactions: Flu-like symptoms common after first dose; usually self-limited
Hypocalcemia: May occur; supplement with calcium and vitamin D
Renal impairment: Assess before each dose; hydrate adequately
Osteonecrosis of the jaw: Risk with dental procedures; consider dental exam before starting
Atypical femur fractures: Risk with prolonged bisphosphonate use
Severe bone, joint, and muscle pain: May occur at any time

Drug Interactions

Aminoglycosides: Additive hypocalcemia effect
Loop diuretics: May increase hypocalcemia risk
Nephrotoxic drugs: Increased risk of renal impairment
NSAIDs: May increase GI adverse effects

Special Populations

Hepatic Impairment: No adjustment needed
Renal Impairment: Reclast contraindicated if CrCl <35 mL/min; Zometa requires dose adjustments
Pregnancy: May cause fetal harm; contraindicated
Lactation: Not recommended
Pediatric: Not approved for children
Elderly: Ensure adequate renal function; hydrate well

Frequently Asked Questions

The infusion takes at least 15 minutes. The most common side effect is an acute-phase reaction (flu-like symptoms) including fever, muscle aches, headache, and joint pain that typically begins within 24 to 72 hours after the first infusion. These symptoms usually resolve within 3 days and are less common with subsequent infusions. Acetaminophen or ibuprofen can help manage these symptoms.

A single annual infusion of Reclast provides bone-protective effects for a full year. After 3 to 5 years of annual infusions, your doctor may consider a drug holiday because zoledronic acid persists in bone tissue for years. Studies have shown residual benefit for 3 or more years after the last infusion.

Yes. Your doctor will typically check serum creatinine (kidney function), calcium, and vitamin D levels before each infusion. The infusion should not be given if creatinine clearance is below 35 mL/min. Any vitamin D deficiency should be corrected before the infusion.

Osteonecrosis of the jaw (ONJ) is a rare condition where jawbone tissue fails to heal after dental procedures. The risk with annual osteoporosis dosing of zoledronic acid is very low (estimated at 1 in 10,000 to 1 in 100,000). The risk is higher in cancer patients receiving more frequent, higher-dose IV bisphosphonates. Maintaining good dental hygiene and completing needed dental work before starting treatment can further reduce this risk.

Reclast is contraindicated in patients with creatinine clearance below 35 mL/min or evidence of acute kidney injury. For patients with mild-to-moderate kidney impairment, adequate hydration before and after infusion is critical. Your doctor will assess your kidney function before each dose.

Questions to Ask Your Doctor

Consider discussing these topics at your next appointment:

✓Should I complete any dental work before receiving my first zoledronic acid infusion?
✓How long should I continue annual infusions before considering a bisphosphonate holiday?
✓Are my vitamin D levels adequate, and do I need supplementation before the infusion?
✓What symptoms after the infusion would require me to contact you?
✓Is my kidney function adequate for this medication?

Schedule an Appointment

Related Health Conditions

This medication is commonly used to treat or manage the following conditions:

Osteoporosis

Osteoporosis weakens bones due to age, hormonal changes, poor diet, medications, certain medical conditions, and lifestyle factors, increasing fracture risk even from minor incidents.

Learn More

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.